23Jan
23Jan
Wasabi Acquires Curio AI from GrayMeta
Wasabi Technologies, the hot cloud storage company, announces the acquisition of Curio AI from GrayMeta, Inc. Terms of the deal were not disclosed. The acquisition includes both the intellectual property and the visionary team behind Curio, including GrayMeta CEO Aaron Edell, who will join Wasabi as Senior Vice President of AI and Machine Learning. Wasabi will incorporate the Curio AI technology into a new class of AI-powered intelligent storage for the Media and Entertainment industry which it plans to release...
20Jan
Myomo Announces Closing of $6 Million Registered Direct Offering of Common Stock Priced At-the-Market
Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it has closed its previously announced registered direct offering of its common stock, priced at-the-market with certain new and existing institutional investors as well as certain insiders of the Company, for the purchase anRead more >>
18Jan
Myomo to raise $6M with eyes on Medicare coverage
Myomo announced today that it entered into securities purchase agreements worth approximately $6 million. The company entered into agreements with certain new and existing institutional investors, plus insiders at Myomo. This agreement includes nearly 1.6 million shares of common stock priced at $3.80 per share. In conjunction with the offering, Myomo disclosed that it expects existing cash plus proceeds to help achieve cash flow breakeven on a quarterly basis. The company anticipates realizing this by the fourth quarter of 2024....
12Jan
5 Buffalo-area startups to watch in 2024
With the Covid-era days of funding a plenty long gone, 2023 marked a tough year for many startups across the country. Some banks and venture capital firms failed, companies laid off staff and businesses shut down. Yet, the environment meant the positive standouts shone all the brighter. Read more >>
10Jan
Corbus Pharma’s IND Application Gets FDA Clearance For Investigational Drug CRB-601
Corbus Pharmaceuticals Holdings, Inc. Tuesday announced FDA clearance for its investigational new drug or IND application of CRB-601, a TGFß blocking monoclonal antibody targeting the integrin avß8. Read more >>
08Jan
Gentex Announces eSight Acquisition Set to Showcase Advanced Vision Tech at CES 2024
Gentex Corporation (NASDAQ: GNTX) announced today the asset acquisition of eSight, a leading provider of vision enhancement technologies, to develop and manufacture the next generation of mobile electronic eyewear designed to help people living with visual impairments. Gentex will prominently feature eSight’s next-gen technology at the Consumer Electronics Show (CES) 2024. Gentex is a technology company and a long-time supplier of electro-optical products for the global automotive, aerospace, and fire protection industries. Read more >>
08Jan
EcoSoul: Making a Difference
Noida-based D2C-first company EcoSoul sells eco-friendly home essentials. And it doesn’t use paper to make them…In just three years since its inception, sustainable home essentials brand EcoSoul Home has sold 967,000 products in over five countries to almost a lakh customers. In the process, the company has contributed to reducing 1,327,528 pounds of plastic, and 1,327,528 carbon emissions. It’s all thanks to the unique business idea of co-workers turned co-founders Rahul Singh and Arvind Ganesan who found a way to...
04Jan
Immusoft To Present on ISP-001 Clinical Trial at WORLDSymposium™ 2024 Conference
Immusoft Corporation, a cell therapy company dedicated to improving the lives of patients with rare diseases, today announced that it will present at the upcoming WORLDSymposium 2024 Conference, held in San Diego, February 4-9, 2024. WORLDSymposium is the largest international gathering of lysosomal disease researchers. Immusoft is developing a new modality of gene encoded medicine that holds the promise of being durable and redosable. The Company’s lead investigational drug candidate ISP-001, is a first-in-class investigational treatment for mucopolysaccharidosis type I...
02Jan